These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 2099071)

  • 1. [The determination of the optimal inoculation dose of an oral cholera chemical bivalent vaccine in a controlled experiment].
    Sumarokov AA; Ivanov NR; Dzhaparidze MN; Reznikov IuB; Rystsova EA; Nikitina GP; Matusevich LIa; Popov AA; Plotnikova MN; Shustov VIa
    Zh Mikrobiol Epidemiol Immunobiol; 1990 Dec; (12):55-62. PubMed ID: 2099071
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The determination of the optimal inoculation dose of an oral cholera bivalent chemical vaccine in a controlled trial of the vaccination of children and adolescents].
    Sumarokov AA; Dzhaparidze MN; Eliseev IuIu; Nikitina GP; Poliakov KA; Kazakova ES; Meleshchenko MV; Tsareva NM; Reznikov IuB; Adamova GV
    Zh Mikrobiol Epidemiol Immunobiol; 1993; (5):55-60. PubMed ID: 8067145
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The characteristics of the reactogenicity and immunological activity of a new cholera bivalent chemical vaccine based on the results of controlled trials].
    Sumarokov AA; Ivanov NR; Dzhaparidze MN; Rystsova EA; Reznikov IuB; Matusevich LIa; Nikitina GP; Eliseev IuIu; Adamova GV; Plotnikova MN
    Zh Mikrobiol Epidemiol Immunobiol; 1991 Jul; (7):55-8. PubMed ID: 1719716
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Reactogenicity and immunological effectiveness of an oral cholera chemical vaccine in a limited controlled experiment with human revaccination].
    Sumarokov AA; Ivanov NR; Lelikov VL; Dzhaparidze MN; Karaeva LT
    Zh Mikrobiol Epidemiol Immunobiol; 1978; (12):87-92. PubMed ID: 371293
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and immunogenicity of oral killed whole cell recombinant B subunit cholera vaccine in Barranquilla, Colombia.
    Concha A; Giraldo A; Castañeda E; Martínez M; de la Hoz F; Rivas F; Depetris A; Svennerholm AM; Sack DA
    Bull Pan Am Health Organ; 1995 Dec; 29(4):312-21. PubMed ID: 8605522
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Biochemical and immunochemical characteristics of a new oral, chemical cholera bivalent vaccine and results of a trial of the preparation on volunteers].
    Dzhaparidze MN; Nikitina GP; Ivanov NR; Rystsova EA; Udalova IB
    Zh Mikrobiol Epidemiol Immunobiol; 1982; (11):29-33. PubMed ID: 6760628
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preliminary assessment of the safety and immunogenicity of live oral cholera vaccine strain CVD 103-HgR in healthy Thai adults.
    Migasena S; Pitisuttitham P; Prayurahong B; Suntharasamai P; Supanaranond W; Desakorn V; Vongsthongsri U; Tall B; Ketley J; Losonsky G
    Infect Immun; 1989 Nov; 57(11):3261-4. PubMed ID: 2807523
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bivalent oral cholera vaccine in participants aged 1 year and older in the Dominican Republic: A phase III, single-arm, safety and immunogenicity trial.
    Cordero De Los Santos L; Feris-Iglesias J; Aloysia D'Cor N; Midde VJ; Patnaik BN; Thollot Y; Rasuli A; Desauziers E
    Hum Vaccin Immunother; 2018 Jun; 14(6):1403-1411. PubMed ID: 29470934
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The vaccine candidate Vibrio cholerae 638 is protective against cholera in healthy volunteers.
    García L; Jidy MD; García H; Rodríguez BL; Fernández R; Año G; Cedré B; Valmaseda T; Suzarte E; Ramírez M; Pino Y; Campos J; Menéndez J; Valera R; González D; González I; Pérez O; Serrano T; Lastre M; Miralles F; Del Campo J; Maestre JL; Pérez JL; Talavera A; Pérez A; Marrero K; Ledón T; Fando R
    Infect Immun; 2005 May; 73(5):3018-24. PubMed ID: 15845509
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vibriocidal antibody responses to a bivalent killed whole-cell oral cholera vaccine in a phase III trial in Kolkata, India.
    Kanungo S; Lopez AL; Ali M; Manna B; Kim DR; Mahapatra T; Holmgren J; Dhingra MS; Weirzba TF; Nair GB; Bhattacharya SK; Clemens JD; Sur D
    PLoS One; 2014; 9(5):e96499. PubMed ID: 24800828
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of a bivalent (CVD 103-HgR/CVD 111) live oral cholera vaccine in adult volunteers from the United States and Peru.
    Taylor DN; Tacket CO; Losonsky G; Castro O; Gutierrez J; Meza R; Nataro JP; Kaper JB; Wasserman SS; Edelman R; Levine MM; Cryz SJ
    Infect Immun; 1997 Sep; 65(9):3852-6. PubMed ID: 9284163
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pasteur oral cholera vaccine: studies of reactogenicity, clinical acceptability and immunogenicity in human volunteers.
    Pitisuttitham P; Migasena S; Prayurahong B; Supanaranond W; Suntharasamai P; Supeeranan L; Chantra A; Naksrisook S
    Southeast Asian J Trop Med Public Health; 1993 Mar; 24(1):126-9. PubMed ID: 8362286
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Construction of novel vaccine strains of Vibrio cholerae co-expressing the Inaba and Ogawa serotype antigens.
    Lebens M; Karlsson SL; Källgård S; Blomquist M; Ekman A; Nygren E; Holmgren J
    Vaccine; 2011 Oct; 29(43):7505-13. PubMed ID: 21807059
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and immunogenicity study of a killed bivalent (O1 and O139) whole-cell oral cholera vaccine Shanchol, in Bangladeshi adults and children as young as 1 year of age.
    Saha A; Chowdhury MI; Khanam F; Bhuiyan MS; Chowdhury F; Khan AI; Khan IA; Clemens J; Ali M; Cravioto A; Qadri F
    Vaccine; 2011 Oct; 29(46):8285-92. PubMed ID: 21907255
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [An oral chemical vaccine from the hypertoxigenic strains of the causative agent of cholera KM-76 Inaba and KM-68 Ogawa].
    Dzhaparidze MN; Naumov AV; Nikitina GP; Meleshchenko MV; Dobrova GV; Zavorotnykh VI; Gracheva VP; Zakharova TL
    Zh Mikrobiol Epidemiol Immunobiol; 1991 Apr; (4):31-3. PubMed ID: 1882603
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intestinal and systemic immune responses in humans after oral immunization with a bivalent B subunit-O1/O139 whole cell cholera vaccine.
    Jertborn M; Svennerholm AM; Holmgren J
    Vaccine; 1996 Oct; 14(15):1459-65. PubMed ID: 8994322
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and immunogenicity of a killed bivalent (O1 and O139) whole-cell oral cholera vaccine in adults and children in Vellore, South India.
    Raghava Mohan V; Raj S; Dhingra MS; Aloysia D'Cor N; Singh AP; Saluja T; Kim DR; Midde VJ; Kim Y; Vemula S; Narla SK; Sah B; Ali M
    PLoS One; 2019; 14(6):e0218033. PubMed ID: 31211792
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and immunogenicity of escalating dosages of a single oral administration of peru-15 pCTB, a candidate live, attenuated vaccine against enterotoxigenic Escherichia coli and Vibrio cholerae.
    Chen WH; Garza J; Choquette M; Hawkins J; Hoeper A; Bernstein DI; Cohen MB
    Clin Vaccine Immunol; 2015 Jan; 22(1):129-35. PubMed ID: 25410205
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PaxVax CVD 103-HgR single-dose live oral cholera vaccine.
    Levine MM; Chen WH; Kaper JB; Lock M; Danzig L; Gurwith M
    Expert Rev Vaccines; 2017 Mar; 16(3):197-213. PubMed ID: 28165831
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Kinetics of antibody-secreting cell and fecal IgA responses after oral cholera vaccination in different age groups in a cholera endemic country.
    Akhtar M; Qadri F; Bhuiyan TR; Akter S; Rafique TA; Khan A; Islam LN; Saha A; Svennerholm AM; Lundgren A
    Vaccine; 2017 Jan; 35(2):321-328. PubMed ID: 27916412
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.